( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
154 | 徐波睡眠期持続性棘徐波を示すてんかん性脳症 | 7 |
154. 徐波睡眠期持続性棘徐波を示すてんかん性脳症
臨床試験数 : 7 / 薬物数 : 4 - (DrugBank : 3) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 7
Showing 1 to 7 of 7 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05301894 (ClinicalTrials.gov) | June 7, 202220220607 | 21/3/202220220321 | Extension Study to Evaluate NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Extension Study to Evaluate NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Cont ... | Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pedia ... | Epileptic Encephalopathy;Continuous Spike and Wave During Sleep | Drug: NBI-827104 | Neurocrine Biosciences | NULL | Enrolling by invitation | 4 Years | N/A | All | 24 | Phase 2 | United States;Denmark;Spain;Switzerland;United Kingdom |
2 | EUCTR2021-006788-11-DK (EUCTR) | 25/03/202220220325 | 11/02/202220220211 | A long-duration study to assess the safety and effectiveness of NBI-827104 in children with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep. A long-duration study to assess the safety and effectiveness of NBI-827104 in children with Epilepti ... | Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep - NBI-827104-CSWS2025 Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pedia ... | Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS) MedDRA version: 20.0;Level: PT;Classification code 10077380;Term: Epileptic encephalopathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep(EECSWS) MedDRA version: 20.0;Le ... | Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a Other descriptive name: N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a Other descriptive name: N-[1 ... | Neurocrine Biosciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 2 | United States;France;Canada;Spain;Denmark;Germany;United Kingdom;Switzerland | ||
3 | EUCTR2020-003141-11-ES (EUCTR) | 02/11/202120211102 | 09/06/202120210609 | A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric ... | Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess th ... | Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS) MedDRA version: 20.0;Level: PT;Classification code 10077380;Term: Epileptic encephalopathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep(EECSWS) MedDRA version: 20.0;Le ... | Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a | Neurocrine Biosciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 2 | France;United States;Canada;Spain;Denmark;Germany;United Kingdom;Switzerland;Italy | ||
4 | EUCTR2020-003141-11-DK (EUCTR) | 03/09/202120210903 | 14/12/202020201214 | A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric ... | Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep - Study to evaluate NBI-827104 versus placebo in pediatric subjects with EECSWS Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess th ... | Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS) MedDRA version: 20.0;Level: PT;Classification code 10077380;Term: Epileptic encephalopathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep(EECSWS) MedDRA version: 20.0;Le ... | Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a | Neurocrine Biosciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France;United States;Canada;Spain;Denmark;Germany;United Kingdom;Switzerland;Italy | ||
5 | NCT04625101 (ClinicalTrials.gov) | April 26, 202120210426 | 6/11/202020201106 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epilep ... | Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess th ... | Epileptic Encephalopathy;Continuous Spike and Wave During Sleep | Drug: NBI-827104;Drug: Placebo | Neurocrine Biosciences | NULL | Completed | 4 Years | 12 Years | All | 24 | Phase 2 | United States;Canada;Denmark;Spain;Switzerland;United Kingdom |
6 | EUCTR2020-003141-11-DE (EUCTR) | 00000000 | 01/10/202120211001 | A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric ... | Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep - Study to evaluate NBI-827104 versus placebo in pediatric subjects with EECSWS Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess th ... | Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS) MedDRA version: 20.0;Level: PT;Classification code 10077380;Term: Epileptic encephalopathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep(EECSWS) MedDRA version: 20.0;Le ... | Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a | Neurocrine Biosciences, Inc. | NULL | NA | Female: yes Male: yes | 24 | Phase 2 | United States;France;Canada;Spain;Denmark;Germany;United Kingdom;Switzerland;Italy | ||
7 | EUCTR2020-003141-11-FR (EUCTR) | 00000000 | 21/04/202120210421 | A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep A study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric ... | Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess th ... | Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS) MedDRA version: 20.0;Level: PT;Classification code 10077380;Term: Epileptic encephalopathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep(EECSWS) MedDRA version: 20.0;Le ... | Product Name: NBI-827104 Product Code: NBI-827104 INN or Proposed INN: n/a | Neurocrine Biosciences, Inc. | NULL | NA | Female: yes Male: yes | 24 | Phase 2 | United States;France;Canada;Spain;Denmark;Germany;Switzerland;United Kingdom;Italy |